<DOC>
	<DOC>NCT00250419</DOC>
	<brief_summary>To determine the safety/tolerability, and immunogenicity of an experimental vaccine given as intramuscular injections followed by electrostimulation in cancer patients.</brief_summary>
	<brief_title>V930 First in Man (FIM) Study (V930-002)(COMPLETED)</brief_title>
	<detailed_description />
	<criteria>Patients must have stages II, III, or IV breast, colorectal, ovaria, of nonsmall cell lung cancer Patients will either be disease free following primary therapy or have advanced disease with a durable response (&gt;3 months) after standard therapy Tumor antigen HER2 and/or CEA must be measurable in the blood or detected by Immunohistochemistry staining of the biopsies obtained from the primary tumor or metastasis Patients with prior treatment with any HER2 and/or CEA containing vaccine Patients who have significant cardiac disease Patients with autoimmune disorders Patients who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>